Bayer exercises option on Micromet BiTE antibody
This article was originally published in Scrip
Bayer Schering Pharma has licensed an anticancer antibody from Micromet, under a deal signed between the two companies in January. Bayer's exercise of its option to license a specific antibody before January 5th, 2010, has triggered a formal collaboration to develop the product, which was generated using Micromet's BiTE antibody technology.
You may also be interested in...
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.